LMO1
Rhombotin-1
Also known as: RBTN1, RBTN1_HUMAN, RHOM1, TTG1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P25800
- Gene
- LMO1
- Ensembl
- ENSG00000166407
- Chromosome
- 11
- Canonical length
- 156 aa
- Protein class
- Cancer-related genes, Disease related genes, Predicted intracellular proteins
OverviewNCBI Gene
This locus encodes a transcriptional regulator that contains two cysteine-rich LIM domains but lacks a DNA-binding domain. LIM domains may play a role in protein interactions; thus the encoded protein may regulate transcription by competitively binding to specific DNA-binding transcription factors. Alterations at this locus have been associated with acute lymphoblastic T-cell leukemia. Chromosomal rearrangements have been observed between this locus and at least two loci, the delta subunit of the T-cell antigen receptor gene and the LIM domain binding 1 gene. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2012]
Canonical amino-acid sequenceUniProt
156 residues, UniProt reviewed canonical sequence.
>P25800|LMO1
1 MMVLDKEDGV PMLSVQPKGK QKGCAGCNRK IKDRYLLKAL DKYWHEDCLK CACCDCRLGE
61 VGSTLYTKAN LILCRRDYLR LFGTTGNCAA CSKLIPAFEM VMRARDNVYH LDCFACQLCN
121 QRFCVGDKFF LKNNMILCQM DYEEGQLNGT FESQVQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LMO1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 28 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 28 nTPM
- tongue: 12 nTPM
- skin: 6.9 nTPM
- hypothalamus: 5 nTPM
- midbrain: 3.2 nTPM
- hippocampal formation: 2.7 nTPM
Single-cell type
- oocytes: 161 nCPM
- retinal pigment epithelial cells: 149 nCPM
- early spermatids: 122 nCPM
- retinal horizontal cells: 64 nCPM
- pancreatic islet cells: 53 nCPM
- late spermatids: 48 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 19 nTPM
- medulla oblongata: 11 nTPM
- thalamus: 11 nTPM
- pons: 11 nTPM
- cerebellum: 7.8 nTPM
- cerebral cortex: 6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.63
- gnomAD pLI
- 0.64
- gnomAD missense Z
- 0.38
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of transcription by RNA polymerase II
- positive regulation of transcription by RNA polymerase II
- regulation of T cell homeostatic proliferation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LMO1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LMO1 as an antibody target. Whether an autoantibody or antibody against LMO1 could matter depends on whether native LMO1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LMO1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LMO1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...